List view / Grid view

Scottish Medicines Consortium (SMC)



NICE recommends Pfizer’s lung cancer drug after price drop

18 August 2016 | By The National Institute for Health and Care Excellence (NICE)

When initially reviewed, the committee concluded that the drug was too expensive compared to the current standard of care. Pfizer submitted further evidence, including a new patient access scheme that provided the drug at a lower price alongside revised analyses, which the committee then concluded could now be considered value…


SMC ‘U-turn’ offers lifeline to Scottish skin cancer patients

8 August 2016 | By Bristol-Myers Squibb

The SMC initially refused access to nivolumab for Scottish patients, having taken a different view to the National Institute for Health and Care Excellence (NICE), which approved it to treat patients in England and Wales. However, following a review of additional evidence, the SMC decision has been reversed, bringing access…